Virus News and Research

Latest Virus News and Research

Cholesterol receptor allows entry of HCV virus into human liver cells

A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.

24 Jan 2012

Voluntary action by two research teams to halt work on H5N1 lauded

A Georgetown University Medical Center professor says the voluntary action taken by two research teams to temporarily halt work involving the highly pathogenic avian influenza H5N1 is "laudable."

24 Jan 2012

Settling controversy surrounding bird flu research will not be easy

The WHO is expected to hold a meeting in February to discuss controversy over recent research on the H5N1 bird flu virus, after the U.S. National Scientific Advisory Board for Biosecurity (NSABB) in December advised the journals Science and Nature to withhold publishing two teams' research on the virus for fear the information could "fall into the wrong hands," a commentary in the Economist's "Babbage" blog states.

24 Jan 2012

New gene therapy shows promise against X-linked retinitis pigmentosa

A new gene therapy method developed by University of Florida researchers has the potential to treat a common form of blindness that strikes both youngsters and adults.

24 Jan 2012

Scientists halt bird flu research for 60 days amid safety concerns

The head of the NIH National Institute of Allergy and Infectious Diseases (NIAID), which funded "two projects that created a highly pathogenic [H5N1] flu virus mutation, has welcomed a two-month moratorium on further research while defending the value and safety of the experiments," the Financial Times reports.

24 Jan 2012

China releases updated statistics on HIV/AIDS

"A total of 28,000 people died of HIV/AIDS in China in 2011, and another 48,000 in the country were found newly infected by the virus, according to an official publication" released on Saturday by China's Ministry of Health, UNAIDS, and the WHO, Xinhua/China Daily reports.

24 Jan 2012

Duke team creates vaccine adjuvant of nanoparticles that target lymph nodes

Researchers at Duke University Medical Center have created synthetic nanoparticles that target lymph nodes and greatly boost vaccine responses, said lead author Ashley St. John, Ph.D., a researcher at Duke-NUS Graduate Medical School.

23 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Debate over publication of bird flu studies continues in journal opinion pieces

Ron Fouchier of Erasmus Medical Center in the Netherlands -- lead researcher of one of two teams that last year reported study results "that showed how the H5N1 [bird flu] virus can be transmitted through airborne droplets between ferrets, a model for studying influenza in humans."

21 Jan 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

More than half of high-risk Americans do not receive HBV vaccination

Although there is an effective vaccine for hepatitis B and public health officials have a strong sense of who is at highest risk for the infectious liver disease, tens of thousands of people in the United States contract the virus every year. According to a new study by researchers at Brown University, missed opportunities to administer the vaccine continue to be a reason why infections persist.

20 Jan 2012

Georgetown professors explore balance of national security and scientific freedom

The U.S. government's request that the journals Science and Nature withhold scientific information related to the genetically modified H5N1 virus because of biosecurity concerns does not violate the First Amendment, say two Georgetown University professors. They caution, however, that a fair, transparent process undertaken by research organizations is preferable to governmental constraints on disseminating scientific information.

19 Jan 2012

New vaccine for deadly meningococcus B

A new study shows that a new 4-component meningococcal (4CMenB) vaccine for teenagers is effective when administered on a schedule of 2 doses from 1 to 6 months apart. María Elena Santolaya, from the Department of Pediatrics, University of Chile, Santiago, and colleagues performed the study, which was published online January 18 in the Lancet.

19 Jan 2012

Study demonstrates possibility of curing hepatitis C without use of interferon

Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').

19 Jan 2012

New combo drug helps suppress hepatitis C genotype 1 infection

A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.

19 Jan 2012

Bristol-Myers Squibb agrees purchase of Inhibitex for $2.5Bn

American pharmaceutical giant Bristol-Myers Squibb has agreed the purchase of US biotech company Inhibitex, in a $2.5Bn (£1.6bn) deal which includes the promising new anti-hepatitis C drug INX-189, first designed and prepared in Cardiff University.

19 Jan 2012

Paragon receives JVAP-CBMS contract from DoD

Paragon Bioservices, Inc., a Baltimore-based CMO focused on the process development and manufacturing of biologics, announced today that it has been awarded a JVAP-CBMS contract from the Department of Defense (DoD) for the vaccine development and subsequent GMP manufacturing of the "VEE Replicon Particle Trivalent Filovirus Vaccine."

18 Jan 2012

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a patent infringement lawsuit against Tekmira Pharmaceuticals Corporation in the U.S. District Court of the District of Massachusetts.

18 Jan 2012

Pevion announces further data from clinical study of PEV7 therapeutic Candida vaccine

Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans against otherwise weak antigens .

17 Jan 2012